First MacTel Patient Receives Encelto Treatment
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
Related Articles
Active lifestyle is tied to reduced visual field decline in primary open angle glaucoma
New research findings reveal that increased physical activity significantly slows visual field loss in patients with glaucoma, highlighting exercise as a potential protective factor.
EyeCon 2025
Practical insights, essential information, in a tropical setting. EyeCon is back on September 26-27, 2025, at Margaritaville Hollywood Beach Resort in sunny Hollywood, Florida! At…
TEASE-3 study: Gildeuretinol shows potential to slow early Stargardt disease progression
LONG BEACH, Calif. — Oral gildeuretinol helped patients with Stargardt disease maintain visual acuity for up to 7 years of treatment, according to a study.…
Study: AI Delivers High Accuracy in IRD Diagnosis
Artificial intelligence (AI) models can detect inherited retinal diseases (IRDs) with striking accuracy, according to a systematic review and meta-analysis published recently in Translational Vision…
A look at pink eye (conjunctivitis)
Pink or red, watery, inflamed eyes are signs of conjunctivitis. Learn how treating symptoms of pink eye at home can be effective.
Efficacy and safety of voretigene neparvovec in RPE65-retinopathy: Results of a phase 3 trial in Japan
We report the efficacy and safety of voretigene neparvovec (VN) as an adeno-associated viral vector-based gene therapy for Japanese patients with inherited retinal dystrophy (IRD)…
Innovations in Refractive Cataract Surgery: Light-Adjustable Lenses – Eyetube
John Doane, MD, joins I. Paul Singh, MD, to discuss how light-adjustable lenses (LAL), and the recently released LAL+, are enhancing refractive outcomes after cataract…
Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI
The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).
Serum gp100 Shows Potential as a Clinical Biomarker for Uveal Melanoma Metastasis
A prospective study found that elevated baseline serum glycoprotein 100 (gp100), a marker of melanocytic differentiation, independently predicted early-stage metastatic progression in patients with uv
A capillary conundrum
Retina Specialist focuses on the latest advances in the diagnosis, medical management and surgical treatment of diseases of the retina, along with practical, real-world advice…
